An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies

Current Opinion in Pharmacology

Volumn 24, Issue , 2015, Pages 52-58

  McClorey, Graham ^a   Wood, Matthew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APATORSEN; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 11; CELL PENETRATING PEPTIDE; COPPER ZINC SUPEROXIDE DISMUTASE; CUSTIRSEN; DRISAPERSEN; DYSTROPHIN; ETEPLIRSEN; LIPOPROTEIN A; LOCKED NUCLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MICRORNA; MICRORNA 122; MIPOMERSEN; MIRAVIRSEN; N ACETYLGALACTOSAMINE; PATISIRAN; PLACEBO; PREALBUMIN; REVUSIRAN; RNA; SMALL INTERFERING RNA; SURVIVAL MOTOR NEURON PROTEIN;

AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; BECKER MUSCULAR DYSTROPHY; CARDIOMYOPATHY; CHRONIC HEPATITIS C; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE ESCALATION; DUCHENNE MUSCULAR DYSTROPHY; FAMILIAL AMYLOIDOSIS; FAMILIAL AMYLOIDOTIC CARDIOMYOPATHY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENE MUTATION; HEART INFARCTION; HUMAN; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; RNA SPLICING; SINGLE DRUG DOSE; SPINAL MUSCULAR ATROPHY; SQUAMOUS CELL LUNG CARCINOMA; VENOUS THROMBOEMBOLISM; ANIMAL; GENETICS;

ANIMALS; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA; RNA SPLICING;

EID: 84939128477     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.07.005     Document Type: Review

References (36)

1. G. Ozcan, B. Ozpolat, R.L. Coleman, A.K. Sood, and G. Lopez-Berestein Preclinical and clinical development of siRNA-based therapeutics Adv Drug Deliv Rev 87 2015 108 119
2. Y. Sekijima, J.W. Kelly, and S. Ikeda Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses Curr Pharm Des 14 2008 3219 3230
3. T. Coelho, D. Adams, A. Silva, P. Lozeron, P.N. Hawkins, T. Mant, J. Perez, J. Chiesa, S. Warrington, E. Tranter, and et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis N Engl J Med 369 2013 819 829
4. K. Fitzgerald, M. Frank-Kamenetsky, S. Shulga-Morskaya, A. Liebow, B.R. Bettencourt, J.E. Sutherland, R.M. Hutabarat, V.A. Clausen, V. Karsten, J. Cehelsky, and et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Lancet 383 2014 60 68
5. A.D. Sniderman, K. Williams, J.H. Contois, H.M. Monroe, M.J. McQueen, J. de Graaf, and C.D. Furberg A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
6. F.J. Raal, R.D. Santos, D.J. Blom, A.D. Marais, M.J. Charng, W.C. Cromwell, R.H. Lachmann, D. Gaudet, J.L. Tan, S. Chasan-Taber, and et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
7. R.D. Santos, F.J. Raal, A.L. Catapano, J.L. Witztum, E. Steinhagen-Thiessen, and S. Tsimikas Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials Arterioscler Thromb Vasc Biol 35 2015 689 699
8. H.R. Buller, C. Bethune, S. Bhanot, D. Gailani, B.P. Monia, G.E. Raskob, A. Segers, P. Verhamme, J.I. Weitz, and F.-A.T. Investigators Factor XI antisense oligonucleotide for prevention of venous thrombosis N Engl J Med 372 2015 232 240
9. T.M. Miller, A. Pestronk, W. David, J. Rothstein, E. Simpson, S.H. Appel, P.L. Andres, K. Mahoney, P. Allred, K. Alexander, and et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study Lancet Neurol 12 2013 435 442
10. E. Huntzinger, and E. Izaurralde Gene silencing by microRNAs: contributions of translational repression and mRNA decay Nat Rev Genet 12 2011 99 110
11. J. Krutzfeldt, N. Rajewsky, R. Braich, K.G. Rajeev, T. Tuschl, M. Manoharan, and M. Stoffel Silencing of microRNAs in vivo with 'antagomirs' Nature 438 2005 685 689
12. M. Petersen, and J. Wengel LNA: a versatile tool for therapeutics and genomics Trends Biotechnol 21 2003 74 81
13. J. Elmen, M. Lindow, A. Silahtaroglu, M. Bak, M. Christensen, A. Lind-Thomsen, M. Hedtjarn, J.B. Hansen, H.F. Hansen, E.M. Straarup, and et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver Nucleic Acids Res 36 2008 1153 1162
14. J. Elmen, M. Lindow, S. Schutz, M. Lawrence, A. Petri, S. Obad, M. Lindholm, M. Hedtjarn, H.F. Hansen, U. Berger, and et al. LNA-mediated microRNA silencing in non-human primates Nature 452 2008 896 899
15. S. Obad, C.O. dos Santos, A. Petri, M. Heidenblad, O. Broom, C. Ruse, C. Fu, M. Lindow, J. Stenvang, E.M. Straarup, and et al. Silencing of microRNA families by seed-targeting tiny LNAs Nat Genet 43 2011 371 378
16. B.C. Bernardo, X.M. Gao, C.E. Winbanks, E.J. Boey, Y.K. Tham, H. Kiriazis, P. Gregorevic, S. Obad, S. Kauppinen, X.J. Du, and et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function Proc Natl Acad Sci U S A 109 2012 17615 17620
17. C.L. Jopling, M. Yi, A.M. Lancaster, S.M. Lemon, and P. Sarnow Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA Science 309 2005 1577 1581
18. T. Shimakami, D. Yamane, R.K. Jangra, B.J. Kempf, C. Spaniel, D.J. Barton, and S.M. Lemon Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex Proc Natl Acad Sci U S A 109 2012 941 946
19. Y.P. Li, J.M. Gottwein, T.K. Scheel, T.B. Jensen, and J. Bukh MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR Proc Natl Acad Sci U S A 108 2011 4991 4996
20. H.L. Janssen, H.W. Reesink, E.J. Lawitz, S. Zeuzem, M. Rodriguez-Torres, K. Patel, A.J. van der Meer, A.K. Patick, A. Chen, Y. Zhou, and et al. Treatment of HCV infection by targeting microRNA N Engl J Med 368 2013 1685 1694
21. S. Ottosen, T.B. Parsley, L. Yang, K. Zeh, L.J. van Doorn, E. van der Veer, A.K. Raney, M.R. Hodges, and A.K. Patick In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122 Antimicrob Agents Chemother 59 2015 599 608
22. A. Aartsma-Rus, I. Fokkema, J. Verschuuren, I. Ginjaar, J. van Deutekom, G.J. van Ommen, and J.T. den Dunnen Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations Hum Mutat 30 2009 293 299
23. N.M. Goemans, M. Tulinius, J.T. van den Akker, B.E. Burm, P.F. Ekhart, N. Heuvelmans, T. Holling, A.A. Janson, G.J. Platenburg, J.A. Sipkens, and et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy N Engl J Med 364 2011 1513 1522
24. S. Cirak, V. Arechavala-Gomeza, M. Guglieri, L. Feng, S. Torelli, K. Anthony, S. Abbs, M.E. Garralda, J. Bourke, D.J. Wells, and et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Lancet 378 2011 595 605
25. J.R. Mendell, L.R. Rodino-Klapac, Z. Sahenk, K. Roush, L. Bird, L.P. Lowes, L. Alfano, A.M. Gomez, S. Lewis, J. Kota, and et al. Eteplirsen for the treatment of Duchenne muscular dystrophy Ann Neurol 74 2013 637 647
26. A. Goyenvalle, G. Griffith, A. Babbs, S. El Andaloussi, K. Ezzat, A. Avril, B. Dugovic, R. Chaussenot, A. Ferry, T. Voit, and et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers Nat Med 21 2015 270 275
27. C.A. Betts, A.F. Saleh, C.A. Carr, S.M. Hammond, A.M. Coenen-Stass, C. Godfrey, G. McClorey, M.A. Varela, T.C. Roberts, K. Clarke, and et al. Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice Sci Rep 5 2015 8986
28. C. Mitrpant, P. Porensky, H. Zhou, L. Price, F. Muntoni, S. Fletcher, S.D. Wilton, and A.H. Burghes Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy PLoS One 8 2013 e62114
29. H. Zhou, N. Janghra, C. Mitrpant, R.L. Dickinson, K. Anthony, L. Price, I.C. Eperon, S.D. Wilton, J. Morgan, and F. Muntoni A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice Hum Gene Ther 24 2013 331 342
30. Y. Hua, K. Sahashi, F. Rigo, G. Hung, G. Horev, C.F. Bennett, and A.R. Krainer Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model Nature 478 2011 123 126
31. C. Zanetta, M. Nizzardo, C. Simone, E. Monguzzi, N. Bresolin, G.P. Comi, and S. Corti Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials Clin Ther 36 2014 128 140
32. H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, and D.G. Anderson Non-viral vectors for gene-based therapy Nat Rev Genet 15 2014 541 555
33. J. Winkler Oligonucleotide conjugates for therapeutic applications Ther Deliv 4 2013 791 809
34. P. Boisguerin, S. Deshayes, M.J. Gait, L. O'Donovan, C. Godfrey, C.A. Betts, M.J. Wood, and B. Lebleu Delivery of therapeutic oligonucleotides with cell penetrating peptides Adv Drug Deliv Rev 2015
35. C. Betts, A.F. Saleh, A.A. Arzumanov, S.M. Hammond, C. Godfrey, T. Coursindel, M.J. Gait, and M.J. Wood Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment Mol Ther Nucleic Acids 1 2012 e38
36. T.P. Prakash, M.J. Graham, J. Yu, R. Carty, A. Low, A. Chappell, K. Schmidt, C. Zhao, M. Aghajan, H.F. Murray, and et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice Nucleic Acids Res 42 2014 8796 8807